Kidney Disease News and Research

RSS

Ampyra receives FDA approval for improving walking in MS patients

The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.

23 Jan 2010

Reducing dietary salt can offer significant health benefits

Reducing salt in the American diet by as little as one-half teaspoon (or three grams) per day could prevent nearly 100,000 heart attacks and 92,000 deaths each year, according to a new study. Such benefits are on par with the benefits from reductions in smoking and could save the United States about $24 billion in healthcare costs, the researchers add.

21 Jan 2010

Genzyme receives PDUFA date from FDA for its Biologics License Application for Lumizyme

Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.

21 Jan 2010

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Amgen today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix® (panitumumab) in combination with chemotherapy for the first and second-line treatment of metastatic colorectal cancer (mCRC) (the PRIME '203' and '181' trials, respectively) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in Orlando, Florida from Jan. 22-24, 2010.

21 Jan 2010

AMAG Pharmaceuticals prices public offering of common stock

AMAG Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $48.25 per share.

21 Jan 2010

Gambro acquires CHF Solutions

Gambro and CHF Solutions, Inc. (CHF) announced today that Gambro has acquired CHF, a medical device company that manufactures and distributes ultrafiltration devices to treat fluid overload.

20 Jan 2010

Carlos Slim Health Institute launches major research project in genomic medicine

Mexican business leader Carlos Slim Hel- today announced the launch of a major research project in genomic medicine that will help accelerate progress in public health in Mexico and around the world.

20 Jan 2010

Movie star attends RSN Renal Teen Prom

For one precious night, movie star Jack Black helped more than 250 teens forget about dialysis and renal disease and enjoy a right of passage most kids take for granted—the prom.

19 Jan 2010

New type of fat-producing cells may speed up treatments for muscular dystrophy and fibrosis

A team of University of British Columbia researchers has identified fat-producing cells that possess "dual-personalities" and may further the development of treatments for muscle diseases such as muscular dystrophy and fibrosis.

19 Jan 2010

CKD patients do not receive adequate end-of-life care

Patients with advanced chronic kidney disease (CKD) often do not receive adequate end-of-life care and are unhappy with the medical decisions made as their conditions worsen, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The findings indicate that end-of-life care should be improved to meet the needs of CKD patients.

18 Jan 2010

JDRF and Animas partner to develop an automated system for better control of type 1 diabetes

The Juvenile Diabetes Research Foundation today announced an innovative partnership with Animas Corporation to develop an automated system to help people with type 1 diabetes better control their disease -- the first step on the path to what would be among the most revolutionary advancements in treating type 1 diabetes: the development of an artificial pancreas, a fully automated system to dispense insulin to patients based on real-time changes in blood sugar levels.

18 Jan 2010

Dartmouth researchers to develop and market a drug throughout Asia for treatment of CKD

Thanks in part to more than a decade of preclinical work by Dartmouth researchers, a Japanese biopharmaceutical firm is preparing to develop and market throughout Asia a drug for the treatment of chronic kidney disease (CKD).

18 Jan 2010

More research needed to determine kidney and renal artery abnormalities, says study

Abnormalities in the kidneys and their blood vessels occur in at least 25% of healthy individuals, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). While most of these conditions are not harmful enough to prevent someone from donating a kidney, future studies are needed to determine their impact on long-term health.

18 Jan 2010

Lead even below level "of concern" for children may impair kidney function

Small amounts of lead in the bodies of healthy children and teens — amounts well below the levels defined as "concerning" by the U.S. Centers for Disease Control and Prevention (CDC) — may worsen kidney function, according to a Johns Hopkins Children's Center study published in the Jan. 11 issue of Archives of Internal Medicine.

12 Jan 2010

American Heart Association supports salt reduction initiative

The American Heart Association (AHA) applauds the efforts of New York City to work with the packaged and restaurant foods industry to reduce the amount of salt in the food supply. These efforts serve an important role in bringing both the public health community and food industry together to create solutions and help Americans live healthier lives.

12 Jan 2010

Proteinuria, a long accepted indicator of heart disease risk, has less impact on African-Americans compared to whites

The cardiovascular risk that is associated with proteinuria, or high levels of protein in the urine, a common test used by doctors as an indicator of increased risk for progressive kidney disease, heart attack and stroke, has race-dependent effects, according to a new study by researchers at Wake Forest University School of Medicine.

12 Jan 2010

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

AMAG Pharmaceuticals, Inc. today provided an update on the commercial launch of Feraheme® (ferumoxytol) Injection for intravenous (IV) use, including preliminary fourth quarter 2009 Feraheme net product revenues estimates, as well as an update on the Company’s international and label expansion efforts.

10 Jan 2010

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 “BRAF Inhibitor in Melanoma” (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.

9 Jan 2010

About 3 million lose health coverage in California

About 3 million poor Californians lost health benefits or access to health care, and thousands more lost their jobs due to state budget cuts imposed six months ago, according to a report released Thursday.

8 Jan 2010

3Sbio submits registrational clinical trial application for Feraheme injection

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a registrational clinical trial to the Chinese State Food and Drug Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous use.

8 Jan 2010

Kidney Disease News and Research

Ampyra receives FDA approval for improving walking in MS patients

Reducing dietary salt can offer significant health benefits

Genzyme receives PDUFA date from FDA for its Biologics License Application for Lumizyme

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

AMAG Pharmaceuticals prices public offering of common stock

Gambro acquires CHF Solutions

Carlos Slim Health Institute launches major research project in genomic medicine

Movie star attends RSN Renal Teen Prom

New type of fat-producing cells may speed up treatments for muscular dystrophy and fibrosis

CKD patients do not receive adequate end-of-life care

JDRF and Animas partner to develop an automated system for better control of type 1 diabetes

Dartmouth researchers to develop and market a drug throughout Asia for treatment of CKD

More research needed to determine kidney and renal artery abnormalities, says study

Lead even below level "of concern" for children may impair kidney function

American Heart Association supports salt reduction initiative

Proteinuria, a long accepted indicator of heart disease risk, has less impact on African-Americans compared to whites

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

About 3 million lose health coverage in California

3Sbio submits registrational clinical trial application for Feraheme injection

Free guide - Everything about renal proximal tubule cells eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News